Method, Development and Validation of Emtricitabine and Tenofovir by Using RP-HPLC in Pharmaceutical Dosage Forms

Authors

  • Rajashakar V
  • S. K. Godasu
  • M. Chinna Eswaraiah

DOI:

https://doi.org/10.37591/rrjodfdp.v5i1.124

Keywords:

Emtricetabine, Tenofovir, RP-HPLC, Buffer

Abstract

A new method was established for simultaneous estimation of Emtricitabine and Tenofovir by RP-HPLC method. The chromatographic conditions were successfully developed for these parathions of Emtricitabine and Tenofovir by using Xterra C185 µm (4.6*250 mm) column, flowrate was1ml/min, mobile phase ratio was phosphate buffer (0.05 M) pH4.6: CAN (55:45% v/v) (pH was adjusted with ortho-phosphoric acid), detection wavelength was 255nm. Theretentiontimewas2.399and3.907 min. for Emtricitabine and Tenofovir, respectively. The percentage purity of EmtricitabineandTenofovirwasfoundtobe100.7%and 101.4%respectively. The analytical method was validated according to ICH guidelines (ICH, Q2(R1)). The linearity ranges were observed at 1–5μg for Emtricitabineand100–500μg for Tenofovir. The precision study was precise, robust, and repeatable. LODvaluewas2.95and3.04, and LOQ value was 9.87and10 respectively. The present work is aimed to develop a new, simple, fast, rapid, accurate, efficient and reproducible spectroscopic method for the simultaneous analysis of Emtricitabine and Tenofovir in API and pharmaceutical dosage form.

 

Keywords: Emtricitabine, Tenofovir, RP-HPLC, buffer

 

Cite this Article

V. Rajashakar, S. K. Godasu, M. Chinna Eswaraiah. Method, Development and Validation of Emtricitabine and Tenofovir by Using RP-HPLC in Pharmaceutical Dosage Forms. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2018; 5(1): 37–41p.

Downloads

Published

2018-07-16

Issue

Vol. 5 No. 1 (2018)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.